Literature DB >> 8195244

In vitro and in vivo studies of antagonistic effects of human growth hormone analogs.

W Y Chen1, N Y Chen, J Yun, T E Wagner, J J Kopchick.   

Abstract

A bovine growth hormone (bGH) analog, bGH-G119R, has been shown to act as a functional antagonist of GH activity both in vitro and in vivo. In the present study, human (h) GH analogs with alterations in the third alpha-helix (G120A, G120R) and N terminus (I4A) were generated. These two regions have been reported to form binding site 2 in hGH, which is involved in in vitro dimerization of the GH receptor (GHR). The biological activities of these hGH analogs were tested in vitro by a radioreceptor assay and an assay to test the ability of the molecules to induce tyrosine phosphorylation of a 93-kDa protein in a human lymphocyte line, IM-9. The growth rate of transgenic mice that express different hGH analogs was used as an in vivo test of the activity of the molecules. The results demonstrated that G120R is a potent hGH antagonist both in vitro and in vivo. Transgenic mice expressing G120R demonstrated a growth-suppressed phenotype. However, I4A, which has been demonstrated to be a potent inhibitor of in vitro GHR dimerization, exhibited full growth promoting activity in transgenic mice. Thus, the ability of hGH analogs to induce GHR dimerization in vitro and the ability to promote growth in vivo are not directly correlated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195244

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  Recombinant analogues of prolactin, growth hormone, and placental lactogen: correlations between physical structure, binding characteristics, and activity.

Authors:  A Gertler
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

2.  Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice.

Authors:  S L Asa; K T Coschigano; L Bellush; J J Kopchick; S Ezzat
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 3.  Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.

Authors:  Nicholas A Tritos; Beverly M K Biller
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  Pharmacotherapy or surgery as primary treatment for acromegaly?

Authors:  D Ferone; A Colao; A J van der Lely; S W Lamberts
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

5.  The growth hormone-encoding gene isolated and characterized from Labeo rohita Hamilton is expressed in CHO cells under the control of constitutive promoters in 'autotransgene' constructs.

Authors:  R Rajesh; K C Majumdar
Journal:  Fish Physiol Biochem       Date:  2008-02-07       Impact factor: 2.794

6.  Growth hormone protects human lymphocytes from irradiation-induced cell death.

Authors:  Laurence Lempereur; Daria Brambilla; Giovanna Maria Scoto; Maria D'Alcamo; Vincent Goffin; Lucia Crosta; Tullio Palmucci; Liborio Rampello; Renato Bernardini; Giuseppina Cantarella
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

Review 7.  Growth hormone receptor modulators.

Authors:  Vita Birzniece; Akira Sata; Ken K Y Ho
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

Review 8.  Rational design of competitive prolactin/growth hormone receptor antagonists.

Authors:  Estelle Tallet; Vincent Rouet; Jean-Baptiste Jomain; Paul A Kelly; Sophie Bernichtein; Vincent Goffin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

Review 9.  Pituitary disorders. Drug treatment options.

Authors:  J J Orrego; A L Barkan
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

Review 10.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.